AMGN — AMGEN INC

Nasdaq · Health Care · Biotechnology · CIK 318154 ·
Last close
$416.18
Market Cap
$224.62B
52W High
$421.79
52W Low
$320.97
ADV30
2,489,058
Next earnings
2026-11-03
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 10,054,000,000 7,243,000,000 3,514,000,000 2,375,000,000 95,639,000,000 13,989,000,000 83,951,000,000
Mar 2026 8,618,000,000 5,874,000,000 2,666,000,000 1,819,000,000 92,504,000,000 12,038,000,000 83,314,000,000
Dec 2025 9,866,000,000 6,890,000,000 2,720,000,000 1,333,000,000 90,586,000,000 9,129,000,000 81,928,000,000
Sep 2025 9,557,000,000 6,475,000,000 2,526,000,000 3,216,000,000 90,141,000,000 9,445,000,000 80,522,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$10,756,000,000
Investing CF
$-2,212,000,000
Financing CF
$-5,316,000,000
CapEx
$-2,159,000,000
Dividends Paid
$-5,203,000,000
Buybacks
EPS Diluted TTM
$14.37
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-22,275,000,000
Inventory
$6,220,000,000
Receivables
$10,227,000,000
ST Investments
EBIT TTM
$12,955,000,000
Pretax Income TTM
$10,287,000,000
Interest Exp TTM
$2,668,000,000
Analysts
29

Yahoo Snapshot (yfinance, live)

Total Revenue
$38,094,999,552
EBITDA
$17,268,000,768
Free Cash Flow
$8,645,624,832
Enterprise Value
$267,298,832,384
Total Cash
$13,989,000,192
Total Debt
$57,303,998,464
Shares Out
539,708,274
Trailing EPS
$16.19
Book Value
$21.62
ROE
91.5%
ROA
8.7%
Div Yield
2.43%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 36,751,000,000 9,080,000,000 7,711,000,000 90,586,000,000 81,928,000,000 9,958,000,000
Dec 2024 33,424,000,000 7,258,000,000 4,090,000,000 91,839,000,000 85,962,000,000 11,490,000,000
Dec 2023 28,190,000,000 7,897,000,000 6,717,000,000 97,154,000,000 90,922,000,000 8,471,000,000
Dec 2022 26,323,000,000 9,566,000,000 6,552,000,000 65,121,000,000 61,460,000,000 9,721,000,000

TTM Snapshot

Revenues TTM
$28,764,000,000
NetIncome TTM
$8,587,000,000
OpCashFlow TTM
$0
Assets (Latest)
$91,839,000,000
Forward EPS
$24.22

Max Pain — expiry 2026-08-21

max pain strike: $375.00 · spot: $417.55 · call oi: 10,198 · put oi: 12,533
Expected Move to 2026-08-21: ±$13.18 (3.16%) — implied range $404.37$430.72 · ATM straddle on $420.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GILD GILEAD SCIENCES, INC. $168.47B $135.87
ARGX ARGENX SE $54.80B $876.00
RVMD Revolution Medicines, Inc. $43.99B $205.26
BIIB BIOGEN INC. $30.86B $208.87
MRNA Moderna, Inc. $25.42B $63.67

News headlines (Yahoo Finance, 1h cache)

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
2026-08-13 13:05 · Yahoo
Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions
2026-08-13 08:05 · Yahoo
BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...
2026-08-13 01:04 · Yahoo
Amgen Stock And The Price Of A Promise
2026-08-12 19:17 · Yahoo
AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD
2026-08-12 08:25 · Yahoo
Amgen (AMGN) Q2 2026 Earnings Call Transcript
2026-08-11 23:57 · Yahoo
Dividend Stocks That Are Paying Investors Cash
2026-08-11 17:56 · Yahoo
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
2026-08-11 13:20 · Yahoo
What Analysts Really Pressed LLY On This Quarter
2026-08-10 23:01 · Yahoo
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
2026-08-10 18:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.